TABLE 3.
Antimicrobial activity of CAZ-AVI and comparators against blaOXA-48-like. ESBL Enterobacterales isolates collected globally in 2016–2020c
| %S | %R | MIC50 | MIC90 | MIC range | |
|---|---|---|---|---|---|
| blaOXA-48-Like, ESBL (−), MBL (−) (N = 150) | |||||
| Amikacin | 76.0 | 20.0 | 2 | >64 | 0.5–>64 |
| Aztreonam | 75.3 | 20.1 | 0.25 | 32 | 0.03–128 |
| CAZ-AVI | 98.7 | 1.3 | 0.5 | 1 | 0.015–>128 |
| Cefepime | 66.0 | 7.3 | 2 | 8 | 0.12–>32 |
| Colistina | 84.0 | 16.0 | 0.5 | >8 | 0.06–>8 |
| Imipenem | 30.0 | 44.0 | 4 | >8 | 0.25–>8 |
| Meropenem | 45.3 | 40.0 | 4 | >16 | 0.03–>16 |
| Pip/Taz | 6.7 | 99.3 | >64 | >128 | 8–>128 |
| Tigecyclineb | 94.0 | 1.3 | 0.5 | 2 | 0.06–8 |
| blaOXA-48-Like, ESBL (+), MBL (−) (N = 1190) | |||||
| Amikacin | 64.6 | 30.7 | 4 | >64 | 0.25–>64 |
| Aztreonam | 1.8 | 97.5 | 128 | >128 | 0.12–>128 |
| CAZ-AVI | 99.1 | 0.9 | 1 | 2 | 0.015–>128 |
| Cefepime | 1.4 | 94.8 | >32 | >32 | 0.12–>32 |
| Colistina | 81.8 | 18.2 | 0.5 | >8 | 0.06–>8 |
| Imipenem | 29.4 | 50.2 | 8 | >8 | 0.12–>8 |
| Meropenem | 22.5 | 65.5 | >8 | >16 | 0.015–>16 |
| Pip/Taz | 1.0 | 98.7 | >64 | >128 | 0.25–>128 |
| Tigecyclineb | 96.0 | 0.5 | 1 | 2 | 0.06–>8 |
| blaOXA-48-Like, ESBL (±), MBL (−) (N = 1340) | |||||
| Amikacin | 65.9 | 32.3 | 4 | >64 | 0.25–>64 |
| Aztreonam | 10.0 | 88.9 | 128 | >128 | 0.03–>128 |
| CAZ-AVI | 99.0 | 1.0 | 1 | 2 | 0.015–>128 |
| Cefepime | 8.7 | 85.0 | >32 | >32 | 0.12–>32 |
| Colistina | 82.0 | 18.0 | 0.5 | >8 | 0.06–>8 |
| Imipenem | 12.9 | 70.5 | 4 | >8 | 0.12–>8 |
| Meropenem | 21.3 | 64.3 | >8 | >16 | 0.015–>16 |
| Pip/Taz | 1.0 | 98.7 | >64 | >128 | 0.25–>128 |
| Tigecyclineb | 95.8 | 0.6 | 1 | 2 | 0.06–>8 |
a
EUCAST breakpoints have been used.
b
FDA-approved breakpoints have been used.
c
N, total number of isolates; S, susceptibility; R, resistance; CAZ-AVI, ceftazidime–avibactam; Pip/taz, piperacillin/tazobactam; ESBL, extended-spectrum β-lactamase; MBL, metallo-β-lactamase.